Ocular Therapeutix, Inc. (OCUL) — Stock Score Summary

Ocular Therapeutix, Inc. (OCUL) has a MoatMap StockRank of 6/100 based on Quality (29/100), Value (36/100), and Momentum (20/100) factor scores. The current signal is STRONG SELL. Ocular Therapeutix is a developmental and early-commercial biopharma company. While its wet AMD pipeline is interesting, it lacks the consistent profitability, high ROIC, and structural pricing power of a true quality compounder under our Terry Smith framework.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. The company's competitive moat is anchored by its proprietary bioresorbable hydrogel platform, which enables sustained-release drug delivery and eliminates the need for daily eye drops. It operates as a leading ophthalmic innovator with a commercialized product portfolio and a high-potential clinical pipeline targeting wet AMD.

Key Financial Metrics

Price$8.35
Market Cap$2.0B
P/E (Forward)-5.76
Price/Book2.90
Return on Equity-68.6%
Return on Invested Capital-33.6%
Debt/Equity13.66
Gross Margin0.0%
Operating Margin-865.5%
Revenue Growth0.8%
Free Cash Flow$-149M

Ocular Therapeutix, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Ocular Therapeutix, Inc.’s (OCUL) StockRank?
MoatMap’s StockRank for Ocular Therapeutix, Inc. (OCUL) is 6/100, with a Strong Sell signal. It is a composite of Quality (29), Value (36), and Momentum (20) factor ranks across MoatMap’s 19,000+ stock universe.
Does Ocular Therapeutix, Inc. have an economic moat?
Ocular Therapeutix, Inc. (OCUL) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Ocular Therapeutix, Inc. a buy, hold, or sell?
MoatMap’s current signal for Ocular Therapeutix, Inc. (OCUL) is Strong Sell, based on a StockRank of 6/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Ocular Therapeutix, Inc. in?
Ocular Therapeutix, Inc. (OCUL) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksOCUL deep dive reportAI ChampionsHow we score stocksSense-check another stock